Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly Change in Receivables of $46000.0 for Q4 2025, down 45.88% year-over-year from $85000.0 in Q4 2024, and up 136.22% quarter-over-quarter from -$127000.0 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Change in Receivables for 3 consecutive years, with $46000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Receivables fell 45.88% year-over-year to $46000.0; the TTM figure through Dec 2025 stood at -$200000.0 (down 208.11% YoY), while the FY2025 annual figure was -$200000.0, down 208.11% from the prior year.
- Change in Receivables grew to $46000.0 in Q4 2025 per INBX's latest filing, from -$127000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $447000.0 in Q4 2023 and bottomed at -$183000.0 in Q1 2025.
- Historically, Change in Receivables has averaged $54500.0 across 3 years, with a median of $55000.0 in 2025.
- Annual changes were most pronounced in 2024 — Change in Receivables tumbled 80.98% — and 2025, when it sank 36.0%.
- Inhibrx Biosciences' Change in Receivables stood at $447000.0 in 2023, then sank by 80.98% to $85000.0 in 2024, then slumped by 45.88% to $46000.0 in 2025.
- Business Quant data shows INBX's Change in Receivables at $46000.0 in Q4 2025, -$127000.0 in Q3 2025, and $64000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Dec 31, 2024 | 85,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Dec 31, 2023 | 447,000.00 |
| Sep 30, 2023 | 4,000.00 |